A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking

EMBO Journal

Volumn 18, Issue 6, 1999, Pages 1660-1672

  Stommel, Jayne M ^a,b   Marchenko, Natalie D ^c   Jimenez, Gretchen S ^a   Moll, Ute M ^c   Hope, Thomas J ^a   Wahl, Geoffrey M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

MDM2; Neuroblastoma; Nuclear export; p53; Tetramerization

Indexed keywords

DIMER; LEPTOMYCIN B; LEUCINE; MONOMER; MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P53; REGULATOR PROTEIN; TETRAMER;

ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DNA BINDING; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN QUATERNARY STRUCTURE; SIGNAL TRANSDUCTION;

NES;

EID: 0033559256     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/18.6.1660     Document Type: Article

References (89)

1. Aladjem, M.I., Spike, B.T., Rodewald, L.W., Hope, T.J., Klemm, M., Jaenisch, R. and Wahl, G.M. (1998) ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr. Biol., 8, 145-155.
2. Askjaer, P., Jensen, T.H., Nilsson, J., Englmeier, L. and Kjems, J. (1998) The specificity of the CRM1-Rev nuclear export signal interaction is mediated by RanGTP. J. Biol. Chem., 273, 33414-33422.
3. Bachelerie, F., Rodriguez, M.S., Dargemont, C., Rousset, D., Thomas, D., Virelizier, J.L. and Arenzana-Seisdedos, F. (1997) Nuclear export signal of IκBα interferes with the Rev-dependent posttranscriptional regulation of human immunodeficiency virus type I. J. Cell Sci., 110, 2883-2893.
4. Bacon, D. and Anderson, W.F. (1988) A fast algorithm for rendering space-filling molecule pictures. J. Mol. Graph., 6, 219-220.
5. Bischoff, J.R., Friedman, P.N., Marshak, D.R., Prives, C. and Beach, D. (1990) Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc. Natl Acad. Sci. USA, 87, 4766-4770.
6. Bogerd, H.P., Fridell, R.A., Benson, R.E., Hua, J. and Cullen, B.R. (1996) Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay. Mol. Cell. Biol., 16, 4207-4214.
7. Bosari, S., Viale, G., Roncalli, M., Graziani, D., Borsani, G., Lee, A.K. and Coggi, G. (1995) p53 gene mutations. p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am. J. Pathol. 147, 790-798.
8. Cheng, R., Ford, B.L., O'Neal, P.E., Mathews, C.Z., Bradford, C.S., Thongtan, T., Barnes, D.W., Hendricks, J.D. and Bailey, G.S. (1997) Zebrafish (Danio rerio) p53 tumor suppressor gene: cDNA sequence and expression during embryogenesis. Mol. Mar. Biol. Biotechnol., 6, 88-97.
9. Chernov, M.V., Ramana, C.V., Adler, V.V. and Stark, G.R. (1998) Stabilization and activation of p53 are regulated independently by different phosphorylation events. Proc. Natl Acad. Sci. USA, 95, 2284-2289.
10. Chemova, O.B., Chernov, M.V., Ishizaka, Y., Agarwal, M.L. and Stark, G.R. (1998) MYC abrogates p53-mediated cell cycle arrest in N (phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification. Mol. Cell. Biol., 18, 536-545.
11. Clore, G.M., Ernst, J., Clubb, R., Omichinski, J.G., Kennedy, W.M., Sakaguchi, K., Appella, E. and Gronenborn, A.M. (1995) Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nature Struct. Biol., 2, 321-333.
12. Crook, T., Marston, N.J., Sara, E.A. and Vousden, K.H. (1994) Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell. 79, 817-827.
13. David-Pfeuty, T., Chakrani, F., Ory, K. and Nouvian-Dooghe, Y. (1996) Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumor cells and in untransformed cells. Cell Growth Differ., 7, 1211-1225.
14. Ferrin, T.E., Huang, C.C., Jarvis, L.E. and Langridge, R. (1988) The MIDAS display system. J. Mol. Graph., 6, 13-27.
15. Fischer, U., Huber, J., Boelens, W.C., Mattaj, I.W. and Luhrmann, R. (1995) The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell, 82, 475-483.
16. Fornerod, M., Ohno, M., Yoshida, M. and Mattaj, I.W. (1997) CRM1 is an export receptor for leucine-rich nuclear export signals. Cell, 90, 1051-1060.
17. Freedman, D.A. and Levine, A.J. (1998) Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol., 18, 7288-7293.
18. Friedman, P.N., Chen, X., Bargonetti, J. and Prives, C. (1993) The p53 protein is an unusually shaped tetramer that binds directly to DNA [published erratum appears in Proc: Natl Acad. Sci. USA 1993, 90, 5878]. Proc. Natl Acad. Sci. USA, 90, 3319-3323.
19. Fritsche, M., Haessler, C. and Brandner, G. (1993) Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents [published erratum appears in Oncogene 1993, 8, 2605]. Oncogene, 8, 307-318.
20. Gerace, L. (1995) Nuclear export signals and the fast track to the cytoplasm. Cell, 82, 341-344.
21. Görlich, D. and Mattaj, I.W. (1996) Nucleocytoplasmic transport. Science, 271, 1513-1518.
22. Hainaut, P., Hall, A. and Milner, J. (1994) Analysis of p53 quaternary structure in relation to sequence-specific DNA binding. Oncogene, 9, 299-303.
23. Halazonetis, T.D. and Kandil, A.N. (1993) Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J., 12, 5057-5064.
24. Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-299.
25. Heyman, R.A., Mangelsdorf, D.J., Dyck, J.A., Stein, R.B., Eichele, G., Evans, R.M. and Thaller, C. (1992) 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell, 68, 397-406.
26. Huang, C.C., Petersen, E.F., Klein, T.E., Ferrin, T.E. and Langridge, R. (1991) Conic: a fast renderer for space-filling molecules with shadows. J. Mol. Graph., 9, 230-236.
27. Hupp, T.R. and Lane, D.P. (1994) Allosteric activation of latent p53 tetramers. Curr. Biol., 4, 865-875.
28. Hupp, T.R., Meek, D.W., Midgley, C.A. and Lane, D.P. (1992) Regulation of the specific DNA binding function of p53. Cell, 71, 875-886.
29. Ishioka, C., Shimodaira, H., Englert, C., Shimada, A., Osada, M., Jia, L.Q., Suzuki, T., Gamo, M. and Kanamaru, R. (1997) Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells. Biochem. Biophys. Res. Commun., 232, 54-60.
30. Jeffrey, P.D., Gorina, S. and Pavletich, N.P. (1995) Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 Å. Science. 267, 1498-1502.
31. Jones, S.N., Roe, A.E., Donehower, L.A. and Bradley, A. (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature, 378, 206-208.
32. Kaghad, M. et al. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 90, 809-819.
33. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R.W. (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311.
34. Khokhlatchev, A.V., Canagarajah, B., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E. and Cobb, M.H. (1998) Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell, 93, 605-615.
35. Kim, F.J., Beeche, A.A., Hunter, J.J., Chin, D.J. and Hope,T.J. (1996) Characterization of the nuclear export signal of human T-cell lymphotropic virus type 1 Rex reveals that nuclear export is mediated by position-variable hydrophobic interactions. Mol. Cell. Biol., 16, 5147-5155.
36. Klotzsche, O., Etzrodt, D., Hohenberg, H., Bohn. W. and Deppert, W. (1998) Cytoplasmic retention of mutant tsp53 is dependent on an intermediate filament protein (vimentin) scaffold. Oncogene, 16, 3423-3434.
37. Ko, L.J. and Prives, C. (1996) p53: puzzle and paradigm. Genes Dev., 10, 1054-1072.
38. Komarova, E.A., Zelnick, C.R., Chin, D., Zeremski, M., Gleiberman, A.S., Bacus, S.S. and Gudkov, A.V. (1997) Intracellular localization of p53 tumor suppressor protein in γ-irradiated cells is cell cycle regulated and determined by the nucleus. Cancer Res., 57, 5217-5220.
39. Kraulis, P. (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr., 24, 946-950.
40. Kubbutat, M.H., Jones, S.N. and Vousden, K.H. (1997) Regulation of p53 stability by Mdm2. Nature, 387, 299-303.
41. Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A.J. and Pavletich, N.P. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274, 948-953.
42. Lee, W., Harvey, T.S., Yin, Y., Yau, P., Litchfield, D. and Arrowsmith, C.H. (1994) Solution structure of the tetrameric minimum transforming domain of p53 [published erratum appears in Nature Struct. Biol. 1995, 2, 81]. Nature Struct. Biol., 1, 877-890.
43. Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell, 88, 323-331.
44. Liang, S.H., Hong, D. and Clarke, M.F. (1998) Cooperation of a single lysine mutation and a C-terminal domain in the cytoplasmic sequestration of the p53 protein. J. Biol. Chem., 273, 19817-19821.
45. Lin, J., Chen, J., Elenbaas, B. and Levine, A.J. (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 EIB 55-kD protein. Genes Dev., 8, 1235-1246.
46. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev., 10, 934-947.
47. Lomax, M.E., Barnes, D.M., Hupp, T.R., Picksley, S.M. and Camplejohn, R.S. (1998) Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni-like family members. Oncogene, 17, 643-649.
48. Lou, M.A. et al. (1997) Novel patterns of p53 abnormality in breast cancer from Taiwan: experience from a low-incidence area. Br. J. Cancer, 75, 746-751.
49. Lu, H., Taya, Y., Ikeda, M. and Levine, A.J. (1998) Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc. Natl Acad. Sci. USA. 95, 6399-6402.
50. Martinez, J.D., Pennington, M.E., Craven, M.T., Warters, R.L. and Cress, A.E. (1997) Free radicals generated by ionizing radiation signal nuclear translocation of p53. Cell Growth Differ., 8, 941-949.
51. Mateu, M.G. and Fersht, A.R. (1998) Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain. EMBO J., 17, 2748-2758.
52. McLure, K.G. and Lee, P.W. (1998) How p53 binds DNA as a tetramer. EMBO J., 17, 3342-3350.
53. Middeler, G., Zerf, K., Jenovai, S., Thulig, A., Tschodrich-Rotter, M., Kubitscheck, U. and Peters, R. (1997) The tumor suppressor p53 is subject to both nuclear import and export and both are fast, energy-dependent and lectin-inhibited. Oncogene, 14, 1407-1417.
54. Moll, U.M., Riou, G. and Levine, A.J. (1992) Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl Acad. Sci. USA. 89, 7262-7266.
55. Moll, U.M., LaQuaglia, M., Benard, J. and Riou, G. (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl Acad. Sci. USA, 92, 4407-4411.
56. 1 checkpoint after DNA damage. Mol. Cell. Biol., 16, 1126-1137.
57. Momand, J., Jung, D., Wilczynski, S. and Niland, J. (1998) The MDM2gene amplification database. Nucleic Acids Res., 26, 3453-3459.
58. Moser, F.G., Dorman, B.P. and Ruddle, F.H. (1975) Mouse-human heterokaryon analysis with a 33258 Hoechst-Giemsa technique. J. Cell Biol., 66, 676-680.
59. Norris, P.S. and Haas, M. (1997) A fluorescent p53GFP fusion protein facilitates its detection in mammalian cells while retaining the properties of wild-type p53. Oncogene, 15, 2241-2247.
60. Oliner, J.D., Pietenpol, J.A., Thiagalingam, S., Gyuris, J., Kinzler, K.W. and Vogelstein, B. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362, 857-860.
61. Osada, M. et al (1998) Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nature Med., 4, 839-843.
62. Ossareh-Nazari, B., Bachelerie, F. and Dargemont, C. (1997) Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science. 278, 141-144.
63. Ostermeyer, A.G., Runko, E., Winkfield, B., Ahn, B. and Moll, U.M. (1996) Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus hy a C-terminal peptide. Proc: Natl Acad. Sci. USA, 93, 15190-15194.
64. Paulson, T.G., Almasan, A., Brody, L.L. and Wahl, G.M. (1998) Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage. Mol. Cell. Biol., 18, 3089-3100.
65. Pfeifer, G.P. and Holmquist, G.P. (1997) Mutagenesis in the P53 gene. Biochim. Biophys. Acta, 1333, M1-M8.
66. Pietenpol, J.A., Tokino, T., Thiagalingam, S., el-Deiry, W.S., Kinzler, K.W. and Vogelstein, B. (1994) Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl Acad. Sci. USA, 91, 1998-2002.
67. Price, B.D., Hughes-Davies, L. and Park, S.J. (1995) Cdk2 kinase phosphorylates serine 315 of human p53 in vitro. Oncogene, 11, 73-80.
68. Roth, J., Dobbelstein, M., Freedman, D.A., Shenk, T. and Levine, A.J. (1998) Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J., 17, 554-564.
69. Sakaguchi, K., Sakamoto, H., Lewis, M.S., Anderson, C.W., Erickson, J.W., Appella, E. and Xie, D. (1997) Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry, 36, 10117-10124.
70. Schlamp, C.L., Poulsen, G.L. Nork, T.M. and Nickells, R.W. (1997) Nuclear exclusion of wild-type p_53 in immortalized human retinoblastoma cells. J. Natl Cancer Inst., 89, 1530-1536.
71. Shaulsky, G., Ben-Ze'ev, A. and Rotter, V. (1990a) Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene, 5, 1707-1711.
72. Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A. and Rotter, V. (1990b) Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol., 10, 6565-6577.
73. Sherr, C.J. (1998) Tumor surveillance via the ARF-p53 pathway. Genes Dev., 12, 2984-2991.
74. Shieh, S.Y., Ikeda, M., Taya, Y. and Prives, C. (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell, 91, 325-334.
75. Soussi, T. and May, P. (1996) Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol., 260, 623-637.
76. Stenmark-Askmalm, M., Stal, O., Sullivan, S., Ferraud, L., Sun, X.F., Carstensen, J. and Nordenskjold, B. (1994) Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur. J. Cancer, 2, 175-180.
77. Sun, X.F., Carstensen, J.M., Zhang, H., Stal, O., Wingren, S., Hatschek, T. and Nordenskjold, B. (1992) Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet, 340, 1369-1373.
78. 1 checkpoint defect of monomeric p53 proteins. Oncogene, 13, 589-598.
79. Ueda, H., Ullrich, S.J., Gangemi, J.D., Kappel, C.A., Ngo, L., Feitelson, M.A. and Jay, G. (1995) Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genet., 9, 41-17.
80. Ullman, K.S., Powers, M.A. and Forbes, D.J. (1997) Nuclear export receptors: from importin to exportin. Cell, 90, 967-970.
81. Varley, J.M. et al. (1996) A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome. Oncogene, 12, 2437-2442.
82. Wahl, G.M., Linke, S.P., Paulson, T.G. and Huang, L.C. (1997) Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv., 29, 183-219.
83. Wang, P., Reed, M., Wang, Y., Mayr, G., Stenger, J.E., Anderson, M.E., Schwedes, J.F. and Tegtmeyer, P. (1994) p53 domains: structure, oligomerization and transformation. Mol. Cell. Biol., 14, 5182-5191.
84. Waterman, J.L., Shenk, J.L. and Halazonetis, T.D. (1995) The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J., 14, 512-519.
85. Wen, W., Meinkoth, J.L., Tsien, R.Y. and Taylor, S.S. (1995) Identification of a signal for rapid export of proteins from the nucleus. Cell, 82, 463-473.
86. Wolff, B., Sanglier, J.J. and Wang, Y. (1997) Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem. Biol., 4, 139-147.
87. Wu, X., Bayle, J.H., Olson, D. and Levine, A.J. (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7, 1126-1132.
88. Yang, J., Bardes, E.S.G., Moore, J.D., Brennan, J., Powers, M.A. and Kornbluth, S. (1998) Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1. Genes Dev., 12, 2131-2143.
89. Zhu, J., Shibasaki, F., Price, R., Guillemot, J.C., Yano, T., Dotsch, V., Wagner, G., Ferrara, P. and McKeon, F. (1998) Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1. Cell, 93, 851-861.